The targeting of FAK/paxillin pathways with some small-molecule drugs has been evaluated in bladder cancer studies with promising preliminary results (Chen et al., 2011; Chiu et al., 2016). This evidence concerns the gene PTK2 and urinary bladder carcinoma.